Osaka-Based Reve21 Obtains Hair Loss Device Rights From Sweden's Dignitana
This article was originally published in PharmAsia News
Executive SummaryOsaka-based Reve21 signed an agreement with Swedish firm Dignitana and obtained exclusive market rights for DigniCap, a scalp cooling device to prevent hair loss in cancer patients undergoing chemotherapy. Composed of a cooling unit with a control panel and a silicon cap, the device is designed to treat two patients simultaneously. DigniCap works to prevent hair loss through cooling scalp and slowing blood flow to follicles. A clinical study conducted by the company shows that among 2,249 patients with breast and ovarian cancers, 1,922 people did not need wigs after receiving the treatment. DigniCap is not yet approved in Japan and Reve21 looks to start Japanese trials within the year with a target market launch in 2011. (Click here for more - Japanese language
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.